Dronedarone - A new alternative for management of atrial fibrillation

Recent Patents on Cardiovascular Drug Discovery

Volumn 5, Issue 1, 2010, Pages 47-53

  Hundal, Mandeep ^a   Garg, Rajeev K ^b  

^a Cheyenne Regional Medical Center   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation; Dronedarone; Rhythm control benzofuran

Indexed keywords

AMIODARONE; DRONEDARONE; MULTAQ; PLACEBO; UNCLASSIFIED DRUG;

CHEMICAL STRUCTURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE CLASSIFICATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; LUNG TOXICITY; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PATENT; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZATION; REVIEW; TORSADE DES POINTES; TREATMENT OUTCOME; VOMITING;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HEART RATE; HUMANS; PATENTS AS TOPIC; RECURRENCE;

EID: 77951115676     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489010790192638     Document Type: Review

References (48)

1. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995; 155: 469-473.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
3. Kannel WB, Abbott RD, Savage DD et al. Coronary heart disease and atrial fibrillation: The Framingham Study. Am Heart J 1983; 106: 389-1386
4. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-484.
5. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952. (Pubitemid 28446646)
6. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as independent risk factor for stroke: The Framingham study. Stroke 1991; 22: 983-988.
7. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109: 1509-1513. (Pubitemid 38420179)
8. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342(13): 913-920
9. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358(25): 2667-2677.
10. Chung MK, Shemanski L, Sherman DG, et al. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: Results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J Am Coll Cardiol 2005; 46(10): 1891-1899.
11. Singh BN. Atrial fibrillation: Epidemiologic considerations and rationale for conversion and maintenance of sinus rhythm. J Cardiovasc Pharmacol Ther 2003; 8 (Suppl 1): S13-S26. (Pubitemid 36898216)
12. Waldo AL. Management of atrial fibrillation: The need for AFFIRMative action. Am J Cardiol 1999; 84: 698-700. (Pubitemid 29417964)
13. Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: Two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009; 2(4): 349-361.
14. Spragg DD, Dalal D, Cheema A, et al. Complications of catheter ablation for atrial fibrillation: Incidence and predictors. J Cardiovasc Electrophysiol 2008; 19: 627-631.
15. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861-1872.
16. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003; 42: 20-29.
17. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997; 30: 791-798.
18. Mason JW. Amiodarone. N Engl J Med 1987; 316: 455-466.
19. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation 1993; 87: 1435-1441.
20. Lalevee N, Nargeot J, Barrere-Lemaire S, Gautier P, Richard S. Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol 2003; 14: 885-890. (Pubitemid 37006354)
21. Gautier P, Guillemare E, Marion A, Bertrand JP, Tourneur Y, Nisato D. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol 2003; 41: 191-202. (Pubitemid 36135243)
22. Altomare C, Barbuti A, Viscomi C, Baruscotti M, DiFrancesco D. Effects of dronedarone on acetylcholine-activated current in rabbit SAN cells. Br J Pharmacol 2000; 130: 1315-1320.
23. + current in guinea pig atrial cells. J Cardiovasc Pharmacol 2000; 36: 802-805.
24. Cha TJ, Ehrlich JR, Chartier D, Qi XY, Xiao L, Nattel S. Kir3-based inward rectifier potassium current: Potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation 2006; 113: 1730-1737.
25. Dobrev D, Friedrich A, Voigt N, et al. The G protein-gated potassium current I(K, ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation 2005; 112: 3697-3706.
26. Chatelain P, Meysmans L, Matteazzi JR, Beaufort P, Clinet M. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol 1995; 116: 1949-1956.
27. Schlama, T., Mettling, A., Karrer, P.: WO0128974 (2001).
28. Schlama, T.: WO0129019 (2001).
29. Gubin, J., Chatelain, P., Lucchetti, J., Rosseels, G., Inion, H.: US5223510 (1993)
30. Gutman, A., Nisnevich, G., Yudovitch, L.: US7312345 (2007).
31. Bourriague-Seve, F., Breul, T.: US6939865 (2005).
32. Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: An emerging agent with rhythm- and rate-controlling effects. J Cardiovasc Electrophysiol 2006; 17: S17-S20.
33. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: Comparative efficacy and results of trials. Am J Cardiol 2003; 91: 15D-26D.
34. Dale KM, White CM. Dronedarone: An amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother 2007; 41 (4): 599-605.
35. Damy T, Pousset F, Caplain H, Hulot JS, Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol 2004; 18: 113-123.
36. Quaglino D, Ha HR, Duner E, et al. Effects of metabolites and analogs of amiodarone on alveolar macrophages: Structure-activity relationship. Am J Physiol Lung Cell Mol Physiol 2004; 287: L438-L447
37. Pantos C, Mourouzis I, Delbruyère M, et al. Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heart. Eur J Pharmacol 2002; 444(3): 191-196.
38. Sicouri S, Moro D, Celestino D, Elizari MV. Dronedarone and amiodarone reduce transmural dispersion of repolarization in the canine heart. Fundam Clin Pharmacol 1999; 13(Suppl 1): 72S-72S.
39. Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007; 64: 785-791.
40. Touboul P, Brugada J, Cappuci A, Crijns HJ, Edvardssom N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: A dose ranging study. Eur Heart J 2003; 24: 1481-1487.
41. Singh BN, Connolly SJ, Crijns HJ, et al. EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357(10): 987-999.
42. Davy JM, Herold M, Radzik D, Timmermans AJM. Effect of dronedarone on exercise in patients with permanent atrial fibrillation. Eur Heart J 2006; 27: 885.
43. Kober L, Torp-Pedersen C, McMurray JJ, et al. Dronedarone Study Group-Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358(25): 2678-2687.
44. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360(7): 668-678.
45. Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: A placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009; 120(13): 1174-1180.
46. Hohnloser SH. New pharmacological options for patients with atrial fibrillation: The ATHENA trial. Rev Esp Cardiol 2009; 62(5): 479-481.
47. Yalta K, Turgut O, Yilmaz MB, Yilmaz A, Tandogan I. Dronedarone: A promising alternative for the management of atrial fibrillation. Cardiovasc Drugs Ther 2009; 23(5): 385-393.
48. Moller M, Torp-Pedersen CT, Kober L. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction: Safety aspects and effect on atrial fibrillation. Congest Heart Fail 2001; 7(3): 146-150.